Goldman Sachs’s Allarity Therapeutics ALLR Stock Holding History

Goldman Sachs’s Portfolio ALLR Stock Details ALLR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,616	Closed	-$24.1K	–	6040
2024 Q4	$24.1K	Buy	+20,616	New	+$27.3K	﹤0.01%	5885

Other funds holding ALLR

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCM

Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Goldman Sachs's ALLR Position: Q1 2025 in Review

Goldman Sachs sold out of Allarity Therapeutics (ALLR) in Q1 2025, closing a stake of 20,616 shares — an estimated $24.1K sold.

Goldman Sachs first reported a position in ALLR in Q4 2024 and held it in 1 quarter. The position peaked at $24.1K in Q4 2024. 9 funds tracked by Wall St. Rank hold ALLR as of Q1 2025.

Goldman Sachs reported no remaining Allarity Therapeutics position as of Q1 2025 after selling out during the quarter.
Goldman Sachs sold 20,616 Allarity Therapeutics shares in Q1 2025, an estimated $24.1K.
Goldman Sachs first reported a position in Allarity Therapeutics in Q4 2024 and held it in 1 quarter.
Goldman Sachs's Allarity Therapeutics position peaked at $24.1K in Q4 2024.
9 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q1 2025.

Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.